BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3464101)

  • 1. Gallium citrate Ga 67 accumulation in pulmonary lesions after chemotherapy (MOPP).
    Wells JD; Huskison WT; Davenport OL
    South Med J; 1986 Oct; 79(10):1293-6. PubMed ID: 3464101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of MOPP chemotherapy in early stage Hodgkin's disease.
    Mauch P; Hellman S
    Hematol Oncol; 1984; 2(1):66-9. PubMed ID: 6376318
    [No Abstract]   [Full Text] [Related]  

  • 3. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract]   [Full Text] [Related]  

  • 4. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease.
    Fuller LM; Hagemeister FB
    Recent Results Cancer Res; 1989; 117():197-204. PubMed ID: 2602645
    [No Abstract]   [Full Text] [Related]  

  • 5. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP
    Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract]   [Full Text] [Related]  

  • 6. Mediastinal Hodgkin's disease. Significance of mediastinal involvement in early stage Hodgkin's disease.
    Mauch P; Hellman S
    Hematol Oncol; 1984; 2(1):69-72. PubMed ID: 6547403
    [No Abstract]   [Full Text] [Related]  

  • 7. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.
    da Cunha MF; Meistrich ML; Fuller LM; Cundiff JH; Hagemeister FB; Velasquez WS; McLaughlin P; Riggs SA; Cabanillas FF; Salvador PG
    J Clin Oncol; 1984 Jun; 2(6):571-7. PubMed ID: 6547167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease.
    Cimino G; Biti GP; Anselmo AP; Maurizi Enrici R; Bellesi GP; Bosi A; Cionini L; Mungai V; Papa G; Ponticelli P
    J Clin Oncol; 1989 Jun; 7(6):732-7. PubMed ID: 2715803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary toxicity following MOPP chemotherapy.
    Millward MJ; Cohney SJ; Byrne MJ; Ryan GF
    Aust N Z J Med; 1990 Jun; 20(3):245-8. PubMed ID: 2196871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoblastic lymphoma following therapy for Hodgkin's disease. A case report.
    Casini M; Pianezze G; Fabris P; Cemin S; Coser P
    Haematologica; 1986; 71(1):50-2. PubMed ID: 3084357
    [No Abstract]   [Full Text] [Related]  

  • 12. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of childhood Hodgkin's disease without radiotherapy.
    van den Berg H; Zsiros J; Behrendt H
    Ann Oncol; 1997; 8 Suppl 1():15-7. PubMed ID: 9187423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of sternum and rib in a patient treated for Hodgkin's disease.
    Blijham GH; Vermeulen A; Mendes de Leon DE
    Cancer; 1985 Nov; 56(9):2292-4. PubMed ID: 3840407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myocardial infarct in a patient with Hodgkin's disease treated with cyclic polychemotherapy].
    Matusewicz W; Drzewoski J; Robak T; Krykowski E
    Kardiol Pol; 1983; 26(7):591-4. PubMed ID: 6689036
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group Study.
    Jones SE; Haut A; Weick JK; Wilson HE; Grozea P; Fabian CJ; McKelvey E; Byrne GE; Hartsock R; Dixon DO; Coltman CA
    Cancer; 1983 Apr; 51(8):1339-47. PubMed ID: 6186355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.